Century Therapeutics, Inc. (IPSC)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.50
- As of
Kresmion compiles this page from IPSC's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Century Therapeutics, Inc. (IPSC): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-02.
See the full IPSC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IPSC on one page. Preview it with sample data, then open it live with a free account.
Preview the IPSC dossierActive events for IPSC
- mediumEarnings above estimates
Q2-2026: Beat consensus by 5.0%, EPS $-0.11 vs $-0.1158 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 60% of IPSC (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 65% of IPSC (2026Q2)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +59% to IPSC (2026Q1)
- mediumEarnings above estimates
Q4-2025: Beat consensus by 23.9% - EPS $-0.22 vs $-0.289 estimate
FREE, NO ACCOUNT
Every event on IPSC, as it fires
You are seeing 5 of 8 events recorded on IPSC since 2026-05-31.
The five above landed across 4 days. The other 3 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IPSC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 15673T100 · 2026Q2 | $12.2M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 15673T100 · 2026Q2 | $10.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 15673T100 · 2026Q2 | $6.6M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 15673T100 · 2026Q2 | $3.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 15673T100 · 2026Q2 | $310K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IPSC
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IPSC against its peers
IPSC's operating margin of -15.8% ranks in the 85th percentile of 16 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | IPSC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 109M USD | 12.1M USD | 81 | 17 |
| Operating margin | -15.8% | -600.9% | 85 | 16 |
| Net margin | -8.8% | -392.9% | 79 | 16 |
| Return on equity | -6.0% | -67.4% | 81 | 17 |
Peers (22): SABS, NWBO, LCTX, FATE, ABEO, QTTB, RCKT, OCGN, CABA, BCYC, ARCT, LRMR, AGEN, VNDA, ANIK, IMRX, ACIU, IRD, PRLD, PROK, GLSI, SRZN. Left out: CUVL (no annual filing), VCRE (no annual filing), VOGX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (IPSC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow IPSC on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to IPSC for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.